To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 366 participants.
Also called NCT06500689
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 366 participants
- Registry
-
NCT06500689
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06500689. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-30 (actual); primary completion 2023-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
- Condition
- Essential Hypertension
- Intervention (Drug)
- Allisartan Isoproxil/Sustained-Release Indapamide
- Intervention (Drug)
- Allisartan Isoproxil
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct06500689- Content hash
7936e5582895be72e4fc11bde9083362f90560cba03d81015f543b40fb3eefc9